In This Article:
The market has climbed by 4.1% over the past week, with every sector up and the Information Technology sector leading the way. In the last year, the market has climbed 25%, and earnings are forecast to grow by 15% annually. Identifying undervalued small-cap stocks with insider buying can be a strategic approach in such a robust market environment.
Top 10 Undervalued Small Caps With Insider Buying In The United States
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Ramaco Resources | 12.0x | 0.9x | 35.99% | ★★★★★★ |
| Columbus McKinnon | 20.5x | 0.9x | 43.64% | ★★★★★★ |
| Titan Machinery | 3.4x | 0.1x | 40.66% | ★★★★★☆ |
| Chatham Lodging Trust | NA | 1.3x | 32.00% | ★★★★★☆ |
| Franklin Financial Services | 9.6x | 1.9x | 39.28% | ★★★★☆☆ |
| MYR Group | 34.1x | 0.5x | 42.35% | ★★★☆☆☆ |
| Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
| Leggett & Platt | NA | 0.4x | -1.92% | ★★★☆☆☆ |
| Alta Equipment Group | NA | 0.1x | -62.86% | ★★★☆☆☆ |
| Delek US Holdings | NA | 0.1x | -106.04% | ★★★☆☆☆ |
Let's explore several standout options from the results in the screener.
AtriCure
Simply Wall St Value Rating: ★★★★★☆
Overview: AtriCure specializes in developing and selling surgical and medical equipment, with a market cap of approximately $2.16 billion.
Operations: AtriCure generates revenue primarily from Surgical & Medical Equipment, with recent figures reaching $429.95 million. The company reported a gross profit margin of 74.84% for the latest period ending June 2024, while net income stood at -$40.12 million, reflecting ongoing challenges in achieving profitability amidst substantial operating expenses and R&D investments.
PE: -29.0x
AtriCure, a small cap in the medical device sector, recently reported Q2 2024 sales of US$116.27 million, up from US$100.92 million a year ago, though net loss widened to US$8.01 million from US$5.12 million. Despite being unprofitable and reliant on external borrowing for funding, insider confidence is evident with significant share purchases over the past year. The company anticipates 2024 revenue between US$456-461 million and has secured regulatory approval in China for its AtriClip device, enhancing its market potential globally.
-
Click to explore a detailed breakdown of our findings in AtriCure's valuation report.
-
Evaluate AtriCure's historical performance by accessing our past performance report.
Bloomin' Brands
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Bloomin' Brands is a restaurant company operating multiple casual dining brands, with a market cap of approximately $2.16 billion.
Operations: The company generates revenue primarily from its U.S. operations ($3.97 billion) and international segments ($615.57 million). The cost of goods sold (COGS) for the latest period is $3.84 billion, resulting in a gross profit of $748.99 million and a gross profit margin of 16.32%.